Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C27H30O16 |
| Molecular Weight | 610.5175 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 10 / 10 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](OC3=C(OC4=C(C3=O)C(O)=CC(O)=C4)C5=CC=C(O)C(O)=C5)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O
InChI
InChIKey=IKGXIBQEEMLURG-NVPNHPEKSA-N
InChI=1S/C27H30O16/c1-8-17(32)20(35)22(37)26(40-8)39-7-15-18(33)21(36)23(38)27(42-15)43-25-19(34)16-13(31)5-10(28)6-14(16)41-24(25)9-2-3-11(29)12(30)4-9/h2-6,8,15,17-18,20-23,26-33,35-38H,7H2,1H3/t8-,15+,17-,18+,20+,21-,22+,23+,26+,27-/m0/s1
| Molecular Formula | C27H30O16 |
| Molecular Weight | 610.5175 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 10 / 10 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
DescriptionCurator's Comment: http://phenol-explorer.eu/contents/polyphenol/296 | https://www.ncbi.nlm.nih.gov/pubmed/22731245
Curator's Comment: http://phenol-explorer.eu/contents/polyphenol/296 | https://www.ncbi.nlm.nih.gov/pubmed/22731245
Rutin, also called rutoside, is the glycoside flavonoid found in a certain fruits and vegetables. Most rutine-rich foods are capers, olives, buckwheat (whole grain flour), asparagus, raspberry.In a clinical trial, rutin was found to aid control of intraocular pressure in patients with primary open angle glaucoma. As a component of dietary supplement Phlogenzym, rutin is used for treatment of osteoarthritis. Rutin is also used for treatment of post-surgical swelling of the arm after breast cancer surgery. Traditionally, rutin is used to prevent mucositis due to cancer treatment, to treat blood vessel disease such as varicose veins, bleeding, hemorrhoids.
CNS Activity
Originator
Sources: https://naldc.nal.usda.gov/download/IND43894155/PDF
Curator's Comment: Rutin was first isolated in 1842 by GFerman chemist AUgust Weiss from garden ruc, Ruta graveolens
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL2622 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12193020 |
13.0 nM [IC50] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | PHLOGENZYM Approved UseTaking rutin by mouth in combination with trypsin and bromelain seems to be about as effective as the medication diclofenac (Voltaren) in relieving pain and improving knee function in people with osteoarthritis. |
|||
| Primary | WOBENZYM Approved UseSwelling in the arm after breast surgery (post-surgical lymphedema). Some early research suggests that taking a specific product (Wobenzym) containing rutin, pancreatin, papain, trypsin, and chymotrypsin daily for 7 weeks reduces swelling in the arm due to breast removal surgery. |
|||
| Primary | Unknown Approved UseUnknown |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
23.5 μg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/11151743/ |
16 mg single, oral dose: 16 mg route of administration: Oral experiment type: SINGLE co-administered: |
QUERCETIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
47.6 μg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/11151743/ |
40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered: |
QUERCETIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
89.9 μg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/11151743/ |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
QUERCETIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
381 μg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/11151743/ |
16 mg single, oral dose: 16 mg route of administration: Oral experiment type: SINGLE co-administered: |
QUERCETIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
636 μg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/11151743/ |
40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered: |
QUERCETIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
1017 μg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/11151743/ |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
QUERCETIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
Overview
| CYP3A4 | CYP2C9 | CYP2D6 | hERG |
|---|---|---|---|
OverviewOther
| Other Inhibitor | Other Substrate | Other Inducer |
|---|---|---|
Drug as perpetrator
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
| inconclusive | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| weak [IC50 111.5 uM] | ||||
| yes [EC50 2.32 uM] | ||||
| yes [IC50 27 uM] | ||||
| yes [IC50 60.7 uM] | ||||
| yes [IC50 7.2 uM] | ||||
| yes | ||||
| yes | ||||
| yes | ||||
| yes | ||||
| yes |
Drug as victim
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
| yes | ||||
| yes | ||||
| yes |
Tox targets
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
PubMed
| Title | Date | PubMed |
|---|---|---|
| Flavonoids suppress human glioblastoma cell growth by inhibiting cell metabolism, migration, and by regulating extracellular matrix proteins and metalloproteinases expression. | 2015-12-05 |
|
| Synthesis, characterization and biological evaluation of Rutin-zinc(II) flavonoid -metal complex. | 2015-09-05 |
|
| Rutin ameliorates cyclophosphamide induced oxidative stress and inflammation in Wistar rats: role of NFκB/MAPK pathway. | 2015-04-25 |
|
| Dietary flavonoids fisetin and myricetin: dual inhibitors of Plasmodium falciparum falcipain-2 and plasmepsin II. | 2014-04 |
|
| Effects of resveratrol and other wine polyphenols on the proliferation, apoptosis and androgen receptor expression in LNCaP cells. | 2014-02-10 |
|
| Toxicity of thienopyridines on human neutrophil granulocytes and lymphocytes. | 2013-06-07 |
|
| Bioactivity-guided fractionation of Phyllanthus orbicularis and identification of the principal anti HSV-2 compounds. | 2012-10 |
|
| Toxicity of clopidogrel and ticlopidine on human myeloid progenitor cells: importance of metabolites. | 2012-09-28 |
|
| Antiplasmodial activity of flavonol quercetin and its analogues in Plasmodium falciparum: evidence from clinical isolates in Bangladesh and standardized parasite clones. | 2012-06 |
|
| Plant polyphenols regulate chemokine expression and tissue repair in human keratinocytes through interaction with cytoplasmic and nuclear components of epidermal growth factor receptor system. | 2012-02-15 |
|
| Differential protective effects of quercetin, resveratrol, rutin and epigallocatechin gallate against mitochondrial dysfunction induced by indomethacin in Caco-2 cells. | 2012-02-05 |
|
| Screening medicinal plants for the detection of novel antimalarial products applying the inhibition of β-hematin formation. | 2011-12-15 |
|
| Plant polyphenols differentially modulate inflammatory responses of human keratinocytes by interfering with activation of transcription factors NFκB and AhR and EGFR-ERK pathway. | 2011-09-01 |
|
| Rutin attenuates cisplatin induced renal inflammation and apoptosis by reducing NFκB, TNF-α and caspase-3 expression in wistar rats. | 2011-09 |
|
| Phenolic compounds from Achillea millefolium L. and their bioactivity. | 2011 |
|
| Structural relationship and binding mechanisms of five flavonoids with bovine serum albumin. | 2010-12-09 |
|
| Gastroprotective effect of rutin against indomethacin-induced ulcers in rats. | 2010-09 |
|
| Bifenthrin-induced oxidative stress in human erythrocytes in vitro and protective effect of selected flavonols. | 2010-03 |
|
| Vitamin E and rutin synergistically inhibit expression of vascular endothelial growth factor through down-regulation of binding activity of activator protein-1 in human promyelocytic leukemia (HL-60) cells. | 2010-02-12 |
|
| Naturally occurring flavonoids attenuate high glucose-induced expression of proinflammatory cytokines in human monocytic THP-1 cells. | 2009-08 |
|
| Flavonoids inhibit histamine release and expression of proinflammatory cytokines in mast cells. | 2008-10 |
|
| Flavonoids as inhibitors of human carbonyl reductase 1. | 2008-07-30 |
|
| Protective effect of rutin, a polyphenolic flavonoid against haloperidol-induced orofacial dyskinesia and associated behavioural, biochemical and neurochemical changes. | 2007-10 |
|
| In vitro anti-HIV and -HSV activity and safety of sodium rutin sulfate as a microbicide candidate. | 2007-09 |
|
| In silico prediction of pregnane X receptor activators by machine learning approaches. | 2007-01 |
|
| Prediction of estrogen receptor agonists and characterization of associated molecular descriptors by statistical learning methods. | 2006-11 |
|
| Comparative studies of some phenolic compounds (quercetin, rutin, and ferulic acid) affecting hepatic fatty acid synthesis in mice. | 2006-10-18 |
|
| Antiparasitic activity of flavonoids and isoflavones against Cryptosporidium parvum and Encephalitozoon intestinalis. | 2006-06 |
|
| Influence of quercetin and rutin on growth and antioxidant defense system of a human hepatoma cell line (HepG2). | 2006-02 |
|
| Inhibition of human cytochrome CYP 1 enzymes by flavonoids of St. John's wort. | 2006-01-16 |
|
| Antitubercular sterols from Thalia multiflora Horkel ex Koernicke. | 2005-10 |
|
| [Effect of polyphenols from the Mediterranean diet on proliferation and mediators of in vitro invasiveness of the MB-49 murine bladder cancer cell line]. | 2005-09 |
|
| Differential inhibition of oxidized LDL-induced apoptosis in human endothelial cells treated with different flavonoids. | 2005-05 |
|
| Dietary rutin, but not its aglycone quercetin, ameliorates dextran sulfate sodium-induced experimental colitis in mice: attenuation of pro-inflammatory gene expression. | 2005-02-01 |
|
| Anti-HIV benzylisoquinoline alkaloids and flavonoids from the leaves of Nelumbo nucifera, and structure-activity correlations with related alkaloids. | 2005-01-17 |
|
| Inhibitory effect of quercetin on carrageenan-induced inflammation in rats. | 2003-12-26 |
|
| Chlorogenic acid, quercetin-3-rutinoside and black tea phenols are extensively metabolized in humans. | 2003-06 |
|
| Search of antimicrobial activity of selected non-antibiotic drugs. | 2003-04-03 |
|
| Flavonoids and nitric oxide synthase. | 2002-12 |
|
| A pharmacophore for human pregnane X receptor ligands. | 2002-01 |
|
| Flavonoids as phospholipase A2 inhibitors: importance of their structure for selective inhibition of group II phospholipase A2. | 1997-06 |
|
| Inhibition of HIV-1 integrase by flavones, caffeic acid phenethyl ester (CAPE) and related compounds. | 1994-08-03 |
|
| Flavones are inhibitors of HIV-1 proteinase. | 1992-10-30 |
|
| Antimicrobial constituents of Gomphrena martiana and Gomphrena boliviana. | 1992-04 |
|
| [Conservative management of lymphedema of the limbs]. | 1991-08-04 |
|
| Differential inhibitory effects of various flavonoids on the activities of reverse transcriptase and cellular DNA and RNA polymerases. | 1990-07-05 |
|
| Effect of benzopyrone derivatives on drug activity and metabolism. | 1986-10-01 |
|
| Inhibitory effect of the flavonoid O-(beta-hydroxyethyl)-rutoside on increased microvascular permeability induced by various agents in rat skin. | 1983 |
|
| Effect of o-(beta-hydroxyethyl)-rutoside in lymphangiography. | 1977-02 |
|
| Metabolism of hydroxyethylrutosides (HR): metabolism of [14C]-HR in man. | 1976 |
Patents
Sample Use Guides
As a dietary supplement and natural nutrient, rutin is administered orally. For osteoarthritis: 2 tablets of a combination product (Phlogenzym), which contains 100 mg of rutin, 48 mg of trypsin, and 90 mg of bromelain, 3 times daily.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/12193020
Inhibition of aldose reductase from rat lens homogenate was measured using DL-glyceraldehyde as a substrate. The reaction was initiated by addition of NADPH at 30°C. After 30 min the reaction was stopped, and 10mM imidazole was added to convert NADP to a fluorescent product. IC50 for rutin was 13 uM.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 17:36:10 GMT 2025
by
admin
on
Mon Mar 31 17:36:10 GMT 2025
|
| Record UNII |
5G06TVY3R7
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
DSLD |
120 (Number of products:1322)
Created by
admin on Mon Mar 31 17:36:10 GMT 2025 , Edited by admin on Mon Mar 31 17:36:10 GMT 2025
|
||
|
WHO-ATC |
C05CA01
Created by
admin on Mon Mar 31 17:36:10 GMT 2025 , Edited by admin on Mon Mar 31 17:36:10 GMT 2025
|
||
|
WHO-VATC |
QC05CA01
Created by
admin on Mon Mar 31 17:36:10 GMT 2025 , Edited by admin on Mon Mar 31 17:36:10 GMT 2025
|
||
|
DSLD |
1394 (Number of products:104)
Created by
admin on Mon Mar 31 17:36:10 GMT 2025 , Edited by admin on Mon Mar 31 17:36:10 GMT 2025
|
||
|
WHO-VATC |
QC05CA51
Created by
admin on Mon Mar 31 17:36:10 GMT 2025 , Edited by admin on Mon Mar 31 17:36:10 GMT 2025
|
||
|
WHO-ATC |
C05CA51
Created by
admin on Mon Mar 31 17:36:10 GMT 2025 , Edited by admin on Mon Mar 31 17:36:10 GMT 2025
|
||
|
NCI_THESAURUS |
C792
Created by
admin on Mon Mar 31 17:36:10 GMT 2025 , Edited by admin on Mon Mar 31 17:36:10 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
RUTIN
Created by
admin on Mon Mar 31 17:36:10 GMT 2025 , Edited by admin on Mon Mar 31 17:36:10 GMT 2025
|
PRIMARY | |||
|
28527
Created by
admin on Mon Mar 31 17:36:10 GMT 2025 , Edited by admin on Mon Mar 31 17:36:10 GMT 2025
|
PRIMARY | |||
|
100000090310
Created by
admin on Mon Mar 31 17:36:10 GMT 2025 , Edited by admin on Mon Mar 31 17:36:10 GMT 2025
|
PRIMARY | |||
|
3535
Created by
admin on Mon Mar 31 17:36:10 GMT 2025 , Edited by admin on Mon Mar 31 17:36:10 GMT 2025
|
PRIMARY | |||
|
153-18-4
Created by
admin on Mon Mar 31 17:36:10 GMT 2025 , Edited by admin on Mon Mar 31 17:36:10 GMT 2025
|
PRIMARY | |||
|
5G06TVY3R7
Created by
admin on Mon Mar 31 17:36:10 GMT 2025 , Edited by admin on Mon Mar 31 17:36:10 GMT 2025
|
PRIMARY | |||
|
205-814-1
Created by
admin on Mon Mar 31 17:36:10 GMT 2025 , Edited by admin on Mon Mar 31 17:36:10 GMT 2025
|
PRIMARY | |||
|
61606
Created by
admin on Mon Mar 31 17:36:10 GMT 2025 , Edited by admin on Mon Mar 31 17:36:10 GMT 2025
|
PRIMARY | |||
|
1606503
Created by
admin on Mon Mar 31 17:36:10 GMT 2025 , Edited by admin on Mon Mar 31 17:36:10 GMT 2025
|
PRIMARY | |||
|
CHEMBL226335
Created by
admin on Mon Mar 31 17:36:10 GMT 2025 , Edited by admin on Mon Mar 31 17:36:10 GMT 2025
|
PRIMARY | |||
|
5280805
Created by
admin on Mon Mar 31 17:36:10 GMT 2025 , Edited by admin on Mon Mar 31 17:36:10 GMT 2025
|
PRIMARY | |||
|
SUB10407MIG
Created by
admin on Mon Mar 31 17:36:10 GMT 2025 , Edited by admin on Mon Mar 31 17:36:10 GMT 2025
|
PRIMARY | |||
|
2213
Created by
admin on Mon Mar 31 17:36:10 GMT 2025 , Edited by admin on Mon Mar 31 17:36:10 GMT 2025
|
PRIMARY | |||
|
D012431
Created by
admin on Mon Mar 31 17:36:10 GMT 2025 , Edited by admin on Mon Mar 31 17:36:10 GMT 2025
|
PRIMARY | |||
|
DTXSID3022326
Created by
admin on Mon Mar 31 17:36:10 GMT 2025 , Edited by admin on Mon Mar 31 17:36:10 GMT 2025
|
PRIMARY | |||
|
m9708
Created by
admin on Mon Mar 31 17:36:10 GMT 2025 , Edited by admin on Mon Mar 31 17:36:10 GMT 2025
|
PRIMARY | Merck Index | ||
|
5G06TVY3R7
Created by
admin on Mon Mar 31 17:36:10 GMT 2025 , Edited by admin on Mon Mar 31 17:36:10 GMT 2025
|
PRIMARY | |||
|
4055
Created by
admin on Mon Mar 31 17:36:10 GMT 2025 , Edited by admin on Mon Mar 31 17:36:10 GMT 2025
|
PRIMARY | |||
|
DB01698
Created by
admin on Mon Mar 31 17:36:10 GMT 2025 , Edited by admin on Mon Mar 31 17:36:10 GMT 2025
|
PRIMARY | |||
|
C819
Created by
admin on Mon Mar 31 17:36:10 GMT 2025 , Edited by admin on Mon Mar 31 17:36:10 GMT 2025
|
PRIMARY | |||
|
9500
Created by
admin on Mon Mar 31 17:36:10 GMT 2025 , Edited by admin on Mon Mar 31 17:36:10 GMT 2025
|
PRIMARY | RxNorm | ||
|
9220
Created by
admin on Mon Mar 31 17:36:10 GMT 2025 , Edited by admin on Mon Mar 31 17:36:10 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
PARENT -> CONSTITUENT ALWAYS PRESENT | |||
|
PARENT -> CONSTITUENT ALWAYS PRESENT | |||
|
PARENT -> CONSTITUENT ALWAYS PRESENT | |||
|
PARENT -> CONSTITUENT ALWAYS PRESENT | |||
|
SOLVATE->ANHYDROUS | |||
|
PARENT -> CONSTITUENT ALWAYS PRESENT | |||
|
|
PARENT -> CONSTITUENT ALWAYS PRESENT |
|
||
|
PARENT -> CONSTITUENT ALWAYS PRESENT |
|
||
|
|
SALT/SOLVATE -> PARENT | |||
|
|
SALT/SOLVATE -> PARENT | |||
|
PARENT -> CONSTITUENT ALWAYS PRESENT | |||
|
PARENT -> CONSTITUENT ALWAYS PRESENT |
CALENDULA OFFICINALIS FLOWER flavonoid
|
||
|
PARENT -> CONSTITUENT ALWAYS PRESENT | |||
|
|
PARENT -> CONSTITUENT ALWAYS PRESENT | |||
|
PARENT -> CONSTITUENT ALWAYS PRESENT |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
METABOLITE -> PARENT |
IN-VIVO
URINE
|
||
|
METABOLITE -> PARENT |
Quantity of quercetin-3-glucuronide in urine of six healthy human subjects 0-24hr (total) after consumption of tomato juice containing 176 micromoles of rutin; Unit: nmoles
IN-VIVO
URINE
|
||
|
METABOLITE -> PARENT |
Cmax: 4.3 +/- 1.5 nM; Tmax: 5.4 +/- 0.2 hr; T1/2: 6.9 +/- 0.3 hr (n=6)
IN-VIVO
PLASMA
|
||
|
METABOLITE -> PARENT |
IN-VIVO
PLASMA; URINE
|
||
|
METABOLITE -> PARENT |
IN-VIVO
URINE
|
||
|
METABOLITE -> PARENT |
Quantity of Isorhamnetin-3-glucuronide in urine of six healthy human subjects 0-24hr (total) after consumption of tomato juice containing 176 micromoles of rutin; Unit: nmoles
IN-VIVO
URINE
|
||
|
METABOLITE -> PARENT |
Cmax: 12 +/- 2 nM; Tmax: 4.7 +/- 0.3 hr; T1/2: 5.7 +/- 0.6 hr (n=6)
IN-VIVO
PLASMA
|
||
|
METABOLITE -> PARENT |
IN-VIVO
URINE
|
||
|
METABOLITE -> PARENT |
Excretion of 3-Hydroxyphenylacetic acid in the urine of human subjects (n=6, 0-24hr total) after rutin (176 micromoles) supplemented tomato juice; Unit: micromoles
IN-VIVO
URINE
|
||
|
METABOLITE -> PARENT |
Quantity of Quercetin-4'-glucuronide in urine of five healthy human subjects 0-24hr (total) after consumption of tomato juice containing 176 micromoles of rutin; Unit: nmoles
IN-VIVO
URINE
|
||
|
METABOLITE -> PARENT |
IN-VIVO
URINE
|
||
|
METABOLITE -> PARENT |
Excretion of 3,4-Dihydroxyphenylacetic acid in the urine of human subjects (n=6, 0-24hr total) after rutin (176 micromoles) supplemented tomato juice; Unit: micromoles
IN-VIVO
URINE
|
||
|
METABOLITE -> PARENT |
IN-VIVO
PLASMA; URINE
|
||
|
METABOLITE -> PARENT |
Excretion of 3-Methoxy-4-Hydroxyphenylacetic acid in the urine of human subjects (n=6, 0-24hr total) after rutin (176 micromoles) supplemented tomato juice; Unit: micromoles
IN-VIVO
URINE
|
||
|
METABOLITE -> PARENT |
IN-VIVO
URINE
|
||
|
METABOLITE -> PARENT |
IN-VIVO
PLASMA; URINE
|
||
|
METABOLITE -> PARENT |
IN-VIVO
PLASMA; URINE
|
||
|
METABOLITE -> PARENT |
Quantity of Quercetin-3'-glucuronide in urine of six healthy human subjects 0-24hr (total) after consumption of tomato juice containing 176 micromoles of rutin; Unit: nmoles
IN-VIVO
URINE
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
IMPURITY -> PARENT |
NMT 2%
USP
|
||
|
|
IMPURITY -> PARENT |
USP
|
||
|
IMPURITY -> PARENT |
NMT 2%
USP
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |